A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma

The chimeric monoclonal antibody cG250 recognizes the CAIX/MN antigen. cG250 induces antibody-dependent cellular cytotoxicity (ADCC) responses in vitro that can be enhanced by IL-2. We studied the effects of adding daily low-dose subcutaneous IL-2 to cG250 for treatment of clear cell renal cell carc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Davis, Ian D., Liu, Zhanqi, Saunders, Wayne, Lee, Fook-Thean, Spirkoska, Violeta, Hopkins, Wendie, Smyth, Fiona E., Chong, Geoffrey, Papenfuss, Anthony T., Chappell, Bridget, Poon, Aurora, Saunder, Timothy H., Hoffman, Eric W., Old, Lloyd J., Scott, Andrew M.
Formato: Artigo
Idioma:Inglês
Publicado em: Academy of Cancer Immunology 2007
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2935743/
https://ncbi.nlm.nih.gov/pubmed/17705350
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados